July 6 (Reuters) – OBSEVA SA:
ANNOUNCES POSITIVE RESULTS FROM TWO PHASE three STUDIES, PRIMROSE 1 AND 2, OF YSELTY® (LINZAGOLIX) FOR TREATMENT OF UTERINE FIBROIDS Supply textual inform materials for Eikon: Additional firm protection: (Gdansk Newsroom)
Our Necessities: The Thomson Reuters Perception Concepts.
